SIMIAN-HUMAN HAV HAVING A CHIMERIC 2C PROTEIN

Abstract: The present invention discloses simian-human hepatitis A virus chimeric genomes which encode a hepatitis A virus having a chimeric 2C protein. The invention further discloses the use of these viruses or the nucleic acid sequence encoding them as vaccines.

Description: Title of Invention SIMIAN-HUMAN HAV HAVINGA CHIMERIC2CPROTEIN This application claims the benefit of U.S. Provisional Application No. 60/015,642 filed April 19, 1996. Field of the Invention The present invention relates to molecular approaches to the development of a live hepatitis A vaccine. In particular, the invention relates to nucleic acid sequences which encode hepatitis A viruses having a chimeric 2C protein. More specifically, the nucleic acid sequences of the invention comprise a genome of a human hepatitis A virus strain which contains a chimeric 2C gene consisting of sequences from both a human strain and the simian AGM-27 strain. The invention further relates to the use of these viruses, or the nucleic acid sequences encoding them, as vaccines. Background of Invention Hepatitis A virus (HAV) is a picornavirus irith a -7.5 kb positive strand RNA genome and is the sole member of the Hepatovirus genus (Francki, R. I. B., et al. (1991) Classification and Nomenclature of Viruses. (Arch. Virol./Suppl. 2). Springer, Vienna). The clinical manifestations of HAV infection in humans can vary greatly, ranging from asymptomatic infection, commonly seen in young children, to fulminant hepatitis, which in some cases can result in death (Ross, B. C, et al. (1991) Adv, Virus Reg t , 39:209-253). In attempting to prevent hepatitis A, three general strategies are possible: 1) increasing hygiene standards; 2) passive immunization of those known to be exposed to HAV with normal human immune globulin; and 3) the development of HAV vaccines. However, because sanitation levels in underdeveloped countries remain low and passive immunization offers little hope for control of endemic hepatitis A since most cases of hepatitis A occur in individuals who do not have a specific exposure history, considerable research efforts have been devoted to the development of either live or killed vaccines. With respect to killed or inactivated vaccines, numerous laboratories have reported the development of inactivated HAV vaccines (see, for example, Binn, L.N. et al. (1986) J. Inf. Dis.. 153:749; Provost, P.J. et al. (1986) J. Med. Virol.. 19:23; Flehmig, B. et al. (1989) Lancet i:1039 and Andre, F.E. et al. (1990) Progress in Med. Virol.. 37:72) and SmithKline Beecham and Merck have recently licensed and sold inactivated HAV vaccines containing different strains of HAV. However, the high cost of inactivated HAV vaccines makes their use in other than high-risk individuals unlikely. In addition, questions concerning the duration of immunity induced by inactivated HAV vaccines suggests that multiple doses may need to be administered to confer continued protection. Thus, for these reasons, the widespread use of live attenuated HAV vaccines in underdeveloped countries where hepatitis A is endemic may be more feasible and more efficacious than use of inactivated vaccines. In attempting to develop a live attenuated vaccine, numerous investigators have selected attenuated hepatitis A viruses by passage of wild-type HAV strains in cell culture (see, for example, Provost et al. (1986) J. Med. Virol.. 20:165-176; Karron, R.A. et al. (1988) _[_ Infect. Dis.. 157:338-345). However, attenuation of HAV strains during adaptation to growth in cell culture has been observed to result in overattenuation such that the attenuated viruses, when administered as live vaccines,are no longer effective inducers of anti-HAV antibodies in vivo (Provost, P.J. et al. (1986) J. Med. Virol.. 20: 165- 175) . A potential alternative approach to the production of a candidate live attenuated vaccine strain which grows sufficiently well in a cell line to make vaccine production economically feasible and which is also infectious, immunogenic and avirulent in humans, iβ the use of recombinant DNA methodology to construct chimeric HAV genomes. Summary of Invention The present invention relates to nucleic acid sequences which comprise a genome of a human hepatitis A strain which contains a chimeric 2C gene consisting of sequences from both the human strain and the simian AOM-27 strain. The nucleic acid sequences of the invention are designated "2C chimeric genomes". It is therefore an object of the invention to provide nucleic acid sequences which encode hepatitis A viruses having a chimeric 2C protein. For the purposes of this application, nucleic acid sequence refers to RNA, DNA, cDNA or any variant thereof capable of directing host organism synthesis of hepatitis A viruses having a. chimeric 2C protein. The invention also relates to hepatitis A viruses encoded by the 2C chimeric genomes. These viruses are designated "2C chimeric hepatitis A viruses." The invention further provides vaccines for use in immunizing a mammal against hepatitis A. In one embodiment, the vaccine comprises a 2C chimeric hepatitis A virus. In a second embodiment, the vaccine comprises a 2C chimeric genome which encodes a hepatitis A virus having a chimeric 2C protein. The invention therefore also relates to methods for preventing hepatitis A in a mammal. In one embodiment, the method comprises administering to a mammal an amount of a 2C chimeric genome of the invention effective to induce protective immunity against hepatitis A. In another embodiment, the method of prevention comprises administering to a mammal a 2C chimeric hepatitis A virus in an amount effective to induce protective immunity against hepatitis A. The invention also provides pharmaceutical compositions comprising the 2C chimeric genome of the invention and/or their encoded hepatitis A viruses. The invention further provides kits comprising the 2C chimeric nucleic acid sequences of the invention. The invention further relates to antibodies to 2C chimeric hepatitis A viruses and to pharmaceutical compositions comprising these antibodies. Description of Figures Figure 1 shows the genomic structure of full- length cDNA clones of chimeras consisting of HAV/7 (white) , a cell culture-adapted variant of wild-type HM- 175 HAV derived by passage of HM-175 35 times in primary African Green Monkey kidney cells (see Table 1 of Cohen et al (1987) Proc. Nat'l Acad. Sci USA. 84:2497-2501 for HAV/7 sequence) , wild-type HM-175 (black) (see Figure 1 of Cohen et al (1987) J. Virol.. 61:50-59 for wild-type HM- 175 sequence) and AGM-27 (grey) (see SEQ. ID. N0:1 of U.S. Patent 5,476,658 for AGM-27 sequence) sequences. The chimeras were constructed using DNA fragments from molecular clones of HAV/7 and wild-type HM-175 and fragments of PCR amplified cDNA from the AGM-27 virus. The 2A/2B junctions in the diagrams presented in this application correspond to the cleavage site designation of Cohen et al. (1987) (J. Virol.. 61:50-59) at nucleotides 3674/3675. However, recent results have shown that the 2A/2B junction is in fact nucleotides 3242/3243. Thus, when reference is made to the "2B gene" or "2B sequence" in this application it refers to the 2B gene as defined by Cohen et al. (J. Virol. 61:50-59) which is in reality a truncated 2B which consists of approximately 42% of the residues at the 3' end of the 2B gene. Figure 2 presents a schematic diagram showing the amino acid sequence differences in the proteins between wild-type HM-175 and AGM-27. The bars mark positions at which the amino acid sequence differs between AGM-27 and wild-type HM-175. There are 30 amino acid differences between the 2C sequences of wild-type HM-175 and AGM-27. Cell culture adaptation of HM-175 to produce HAV/7 resulted in three amino acid changes in 2C at residues 31, 76 and 190. When the comparison is between HAV/7 and AGM-27, there are 31 amino acid differences. Amino acid residues 31 and 190, which are the same in wild-type HM-175 and AGM-27, differ between HAV/7 and AGM- 27. Amino acid residue 76, which differs between wild- type HM-175 and AGM-27, is the same in HAV/7 and AGM-27. The asterisks mark the sites of the three mutations that are critical for growth of HAV/7 in cell culture (nts 3889 in 2B and 4087 and 4222 in 2C) (Emerson, S. U., et al. (1992) J. Virol.. 66:650-654). The locations of the two conserved putative NTP-binding motifs are shown with arrows. The amino acid sequence differences in 2C between HM-175 (either wild-type or HAV/7) and AGM-27 are clustered at the amino-terminal and carboxy-terminal ends of the protein. The mutation at position 3889 in the 2B gene, which greatly enhances the growth of human HAV in cell culture, is absent in AGM-27. Figure 3 shows the results of a radioimmunofocus assay comparing the sizes of the foci formed by HAV/7, AGM-27 and the GR2 chimera which contains the AGM-27 2C sequence in the HAV/7 background. Figures 4 shows the results of a radioimmunofocus assay comparing focus size of chimeras that differ in the truncated 2B gene sequence and/or the 2C gene sequence. (A) HAV/7, (B) GR2, (C) GR3, (D) GR4, (E) GR15 and (F) GR9. Figure 5 shows a hybridization assay comparing the growth rates of HAV chimeras which differ only in the sequence of the 2C gene. The chimeras contained either the cell culture-adapted HM-175 (HAV/7) , wild-type HM-175 (36Y) or AGM-27 2C sequence in the HAV/7 background (GR2) . Viral RNA was quantified by slot blot hybridization followed by autoradiography and densitometry analysis. In the bar diagram identifying the virus genotype, AGM-27 sequences are shaded in grey and the four boxes shown in each diagram indicate from left to right (5'—»>3' ) : HAV/7 genomic sequence 5' of the truncated 2B gene, truncated 2B gene, 2C gene and HAV/7 genomic sequence 3' of the 2C gene. The demarcations of the truncated 2B gene and of the 2C gene as shown in the bar diagrams are not drawn to scale. Figure 6 shows results of a hybridization assay of growth curves of HAV/7, the simian-human chimera GR2, and the intragenic 2C chimeras, GR3 and GR4. Viral RNA was quantified by slot blot hybridization followed by autoradiography and densitometry analysis. In the bar diagram identifying the virus genotype, AGM-27 sequences are shaded in grey and the four boxes shown in each diagram indicate from left to right (5'—+3'): HAV/7 genomic sequence 5' of the truncated 2B gene, truncated 2B gene, 2C gene and HAV/7 genomic sequence 3' of the 2C gene. The demarcations of the truncated 2B gene and of the 2C gene as shown in the bar diagrams are not drawn to scale. Figure 7 shows the results of a hybridization assay of growth curves of HAV/7 and chimeras containing the truncated AGM-27 2B gene (GR15) , the 2C gene (GR2) or the truncated 2B gene and the 2C gene (GR9) in the HAV/7 background. Viral RNA was quantified by slot blot hybridization followed by autoradiography and densitometry analysis. In the bar diagram identifying the virus genotype, AGM-27 sequences are shaded in grey and the four boxes shown in each diagram indicate from left to right (5'— * 3 « ): HAV/7 genomic sequence 5' of the truncated 2B gene, truncated 2B gene, 2C gene and HAV/7 genomic sequence 3' of the 2C gene. The demarcations of the truncated 2B gene and of the 2C gene as shown in the bar diagrams are not drawn to scale. Figures 8A and 8B show biochemical (ICD levels), serological (anti-HAV) , histopathological and PCR analyses of two tamarins 782 (Figure 8A) and 783 (Figure 8B) inoculated with the GR2 chimera which contains the AGM-27 2C gene in the HAV/7 background. The ICD serum enzyme levels were measured in international units per ml (IU/ml) . A + in the row marked "anti-HAV" indicates samples that were positive for anti-HAV antibodies as determined by commercial assay. The histopathology scores correspond to mild hepatitis (1+) , mild to moderate hepatitis (2+) , moderately severe hepatitis (3+) and severe hepatitis (4+) . The "ND" designation signifies that liver histology analysis was not performed for these samples. For the PCR analyses, an open circle indicates that the stool sample analyzed was completely negative for HAV after two steps of nested PCR; a half-closed circle indicates that the stool sample was positive for HAV after two steps of nested PCR and a closed circle indicates that the stool sample was positive for HAV after one step of PCR. Figures 9A and 9B show biochemical (ICD levels) serological (anti-HAV) , histopathological and PCR analyses of two tamarins, 808 (Figure 9A) and 790 (Figure 9B) , inoculated with the GR3 chimera which contains sequence from nt 3996-4357 of the AGM-27 2C gene in the HAV/7 background. The ICD serum enzyme levels were measured in international units per ml (IU/ml) . A + in the row marked "anti-HAV" indicates samples that were positive for anti- HAV antibodies as determined by commercial assay. The "ND" designation signifies that liver histology analysis was not performed for these samples. For the PCR analyses, an open circle indicates that the stool sample analyzed was completely negative for HAV after two steps of nested PCR; a half-closed circle indicates that the stool sample was positive for HAV after two steps of nested PCR and a closed circle indicates that the stool sample was positive for HAV after one step of PCR. Figures IOA and 10B show biochemical (ICD levels) , serological (anti-HAV) , histopathological and PCR analyses of two tamarins, 799 (Figure IOA) and 818 (Figure 10B) , inoculated with the GR4 chimera which contains sequence from nt 4354-4981 of the AGM-27 2C gene in the HAV/7 background. The ICD serum enzyme levels were measured in international units per ml (IU/ml) . A + in the row marked "anti-HAV" indicates samples that were positive for anti-HAV antibodies as determined by commercial assay. The histopathology scores correspond to mild hepatitis (1+) , mild to moderate hepatitis (2+) , moderately severe hepatitis (3+) and severe hepatitis (4+) . The "ND" designation signifies that liver histology analysis was not performed for these samples. For the PCR analyses, an open circle indicates that the stool sample analyzed was completely negative for HAV after two steps of nested PCR; a half-closed circle indicates that the stool sample was positive for HAV after two steps of nested PCR and a closed circle indicates that the stool sample was positive for HAV after one step of PCR. Figures 11A-11D show biochemical, serological (anti-HAV) and histopathological analyses of two chimpanzees, 1558 (Figures IIA and IIC) and 1564 (Figures IIB and IID) , inoculated with the GR4 chimera. In Figures IIA and IIB, the biochemical responses are shown as ICD levels where the ICD serum enzyme levels were measured in international units per ml (IU/ml) . In Figures IIC and IID, the biochemical responses are shown as ALT levels where the ALT levels were measured in international units/ml. A + in the row marked "anti-HAV" indicates samples that were positive for anti-HAV antibodies as determined by commercial assay. The histopathology scores correspond to mild hepatitis (1+) , mild to moderate hepatitis (2+) , moderately severe hepatitis (3+) and. severe hepatitis (4+) . The "ND" designation signifies that liver histology analysis was not performed for these samples. Figures 12A and 12B show biochemical (ALT levels) , serological (anti-HAV) and histopathological analyses of two chimpanzees 1545 (Figure 12A) and 1547 (figure 12B) inoculated with the GR2 chimera. A + in the row marked "anti-HAV" indicates samples that were positive for anti-HAV antibodies as determined by commercial assay. The histopathology scores correspond to mild hepatitis (1+) , mild to moderate hepatitis (2+) , moderately severe hepatitis (3+) and severe hepatitis (4+) . The "ND" designation signifies that liver histology analysis was not performed for these samples. Figures 13A-13D show the complete nucleotide and predicted amino acid sequences for wild-type HAV HM-175. Figure 14 shows the results of a comparison between the genome sequences of wild-type (WT) HAV HM-175 (shown in Figures 13A-13D) and attenuated (attenuated) cell-culture adapted HAV/7 where the difference between the two genomes are indicated in the columns marked NT and attenuated. Nucleotide positions correspond to numbering for wild-type HM-175 shown in Figures 13A-13D. Figures 15A-15D show the nucleotide sequence of greater than 99% of the entire genome of AGM-27. The sequence determined for AGM-27 starts from nucleotide 59 according to the nomenclature for wild-type HM-175. Description of Invention The present invention relates to nucleic acid sequences which encode a hepatitis A virus having a chimeric 2C protein. More specifically, the invention relates to nucleic acid sequences which comprise a genome of human hepatitis A strain having a chimeric 2C gene which consists of sequences from both the human strain and the simian AGM-27 strain. In a preferred embodiment, the human hepatitis A strain is an attenuated hepatitis A strain such as MRC5 or HAV/7. In a more preferred embodiment, the attenuated human hepatitis A strain is HAV/7 (Cohen et al. (1987) Proc. Natl. Acad. Sci. USA. 84:2497-2501). Thus, in a preferred embodiment, the 2C chimeric genomes of the invention comprise a genome of the HAV/7 strain having a chimeric 2C gene which consists of sequences from both the HAV/7 strain and the simian AGM-27 strain. Chimeras of the invention can be generated from the pGRl, pGR2 and pHAV/7 full-length clones presented herein in the Examples section through the use of PCR and cloning techniques. Chimeras of the invention include chimeras 1-18, which are generated by PCR amplification of HAV/7 sequence using primers with engineered restriction sites followed by subcloning into the pGR2 background. # AGM-27- AGM-27 2C Amino specific 2C Amino HAV/7 Region Acid Sequence Acid Residues Chimera # Amplified in Chimera in Chimera 1 PpuMl to Dral residues 48 - 328 23 2 PpuMl to Bell residues 63 - 328 20 3 PpuMl to Xmnl residues 84 - 328 18 4 PpuMl to Sal I residues 98 - 328 16 5 Dral to Aflll residues 1 - 49 and 121 - 328 20 6 Bell to Afiπ residues 1 - 64 and 121 - 328 24 7 Xmnl to Aflll residues 1 - 86 and 121 - 328 26 8 Sail to Aflll residues 1 - 99 and 121 - 328 27 9 Dral to EcoRI residues 1-49 7 10 Bell to EcoRI residues 1 - 64 11 11 Xmnl to EcoRI residues 1 - 86 13 12 Sail to EcoRI residues 1 - 99 14 13 Hinfl to EcoRI residues 1 - 283 22 14 AfUII to EcoRI residues 1 - 294 24 15 Ball to EcoRI residues 1 - 304 25 16 AfUI to Hinfl residues 1 - 120 and 283 - 328 25 17 Aflll to AfUII residues 1 - 120 and 294 - 328 aV# 18 Aflll to Ball residues 1 - 120 and 303 - 328 Restriction sites used in AGM-27 for generating these chimeras are: Dral nucleotides 4136 - 4141 Bell nucleotides 4181 - 4186 Xmnl nucleotides 4245 - 4254 Sail nucleotides 4287 - 4292 Hinfl nucleotides 4841 - 4845 AfUII nucleotides 4873 - 4878 Ball nucleotides 4901 - 4906 PflMl nucleotides 4205 - 4215 All these sites, with the exception of PflMl * are present in the AGM-27 sequence but not in the HAV/7 sequence. These restriction sites are engineered at the analogous positions in the pHAV/7 2C gene by primer- directed mutagenesis using PCR. Fragments of pHAV/7 2C sequence are amplified by PCR using the primers with engineered restriction sites and the PCR products are then digested with the appropriate restriction enzymes and cloned into the pGR2 background. Where the restriction enzymes to be utilized in constructing the chimeras of the invention recognize multiple sites in the HAV/7 genome, one can subclone the 2C gene into a suitable vector prior to generation of the chimeras. Suitable vectors include, but are not limited to, plasmids, PUC vectors (Gibco-BRL) , pCRII (Invitrogen) , pGEM vectors (Promega) and pBS vectors (Stratagene) . Additional chimeras of the invention include chimeras 19-21, which are generated by substituting portions of the AGM-27 2C gene for the corresponding portion of the HAV/7 2C gene in, for example, the pGRl construct. If AGM-27- AGM-27 2C Amino specific 2C Amino pGR2 Region Acid Sequence Acid Residues Chimera 0 Amplified jn Chujera in Chimera 19 PpuMl to PflMl residues 1 - 70 12 20 PflMl to Aflll residues 74 - 120 5 21 PflMl to EcoRI residues 74 - 328 18 Chimeras 19-21 are constructed by engineering a PflMl site into the AGM-27 2C gene. The appropriate segment of the pGR2 2C gene is then amplified by PCR using a primer with an engineered PflMl restriction site and the resulting PCR product is digested with the appropriate enzymes and subcloned into the pGRl background. Since the HAV 2C gene encodes 335 amino acids, it is understood by those of ordinary skill in the art that the amino acid residues in the chimeras of the invention that are not from AGM-27 are from HAV/7. Thus for example, in chimera #19, 2C amino acids 1-70 are from AGM-27 and amino acids 71-335 are from HAV/7. In one embodiment the chimeras of the present invention encode at least one and no greater than thirty one of the AGM-27 2C amino acid residues which are different from the amino acids present in the corresponding amino acid sequence of HAV/7; in a more preferred embodiment, the chimeras encode between about 5 to about 25 of the AGM-27 2C amino acid residues which are different from the amino acids present in the corresponding amino acid sequence of HAV/7; and in a most preferred embodiment, the chimeras encode between about 10 to about 20 of the AGM-27 2C amino acid residues which are different from the amino acids present in the corresponding amino acid sequence of HAV/7. In addition, the column marked "#AGM-27-specific 2C Amino Acid Residues in Chimera" indicates the number of AGM-27 2C amino acid residues present in the chimera which are different from the amino acid residues present in the corresponding amino acid sequence of HAV/7. In an alternative embodiment, 2C chimeric genomes of the invention can be generated using fusion recombinant PCR techniques. For example, a fragment containing HAV/7 sequence corresponding to sequences upstream of the PpuMl site to any nucleotide in the 2C gene can be generated by PCR amplification of HAV/7 plasmid DNA using appropriate primers. The reverse primer in this reaction would have 5' -add-on sequences corresponding to AGM-27 sequences just 3' to the gene fusion junction. Similarly, AGM-27 sequence corresponding to sequences from the desired gene fusion junction to sequences downstream of the EcoRI restriction site near the 3' end of the 2C gene can be generated using plasmid pGR2 as a template. The forward primer in this reaction would have 5'-add-on sequences corresponding to HAV/7 sequences just 5' to the gene fusion junction. This primer can be the complement of the reverse primer used for amplification of the HAV/7 sequence. The products of these two PCR reactions would have overlapping sequence which would include the gene fusion junction. The overlapping sequence can be extended by a DNA polymerase to generate a product that is the sum of the two overlapping fragments (i.e. the 2C gene from 5' of the PpuMl site to sequences just 3' of the EcoRI site) . This gene fusion PCR product can be amplified by standard PCR; the forward primer in this reaction may include the PpuMl site and the reverse primer may include the EcoRI site. The PCR amplified fragment containing the intact hybrid 2C gene would then be digested with PpuMl and EcoRI and subcloned into a modified HAV/7 clone (e.g. 32Y or pGRl or pGR2) . Using such gene fusion recombinant PCR techniques, chimeras which contain, for example, AGM-27 sequence from amino acid 90 - 328 (which includes 17 of the 31 amino acid differences in 2C between HAV/7 and AGM-27) or AGM-27 sequence from amino acid 267 - 328 (which includes 10 of the 31 amino acid differences in 2C between HAV/7 and AGM- 27) can be generated. Alternatively, chimeras containing different amounts of AGM-27 sequence at the amino-terminal end of the 2C protein can also be generated using similar techniques; in this case, the fragment containing the PpuMl site would be amplified by PCR using pGR2 as a template and the fragment containing the EcoRI site would be amplified using HAV/7 as a template. Of course, those of ordinary skill in the art would readily understand that the chimeras of the present invention could also be produced by other techniques common to molecular biology such as site-directed mutagenesis. The present invention further relates to the production of 2C chimeric viruses from the nucleic acid sequences described herein. In one embodiment, the 2C chimeric genomes of the invention can be inserted into an expression vector that functions in eukaryotic cells. Examples, of such vectors include, but are not limited to, plasmid expression vectors and vaccinia virus vectors. The 2C chimeric genome contained in the recombinant expression vector can also be transcribed in vitro by methods known to those of ordinary skill in the art in order to produce RNA transcripts which encode the 2C chimeric hepatitis A viruses of the invention. The 2C chimeric hepatitis A viruses of the invention may then be produced by transfecting cells by methods known to those of ordinary skill in the art with either the in vitro transcription mixture containing the RNA transcripts or with the recombinant expression vectors containing the 2C chimeric genome. Such methods include, but are not limited to, electroporation, and lipofection and transfection with DEAE-dextran. Cells suitable for in vitro transfection with the RNA transcripts and recombinant expression vectors of the present invention include eukaryotic cell lines, cells put into primary culture from a host, or cells resulting from passage of the primary culture. Examples of preferred cells are MRC-5, AGMK, FRhK-4 and BSC-1 cells. The 2C chimeric virus so generated can be tested for virulence phenotype by administering the 2C chimeric virus to tamarins and examining the livers of the tamarins for evidence of pathology and/or the serum for biochemical evidence of hepatitis as measured by levels of liver enzymes such as isocitrate dehydrogenase and alanine aminotransferase and the viruses can be tested for their growth in cell culture by techniques such as RIFA or slot blot hybridization as described in Examples section. The 2C chimeric viruses produced from the chimeric sequences of the invention may be purified or partially purified from the transfected cells by methods known to those of ordinary skill in the art such as those described in Andre et al. (Prog. Med. Virol.. (1990) 37:72-95) and Provost et al. (J. Med. Virol.. (1986) 19:23-20, both of which are hereby incorporated by reference. In a preferred embodiment, the 2C chimeric viruses are partially purified prior to their use as immunogens in the pharmaceutical compositions and vaccines of the present invention. The present invention therefore relates to the use of 2C chimeric viruses as immunogens in live vaccines to prevent hepatitis A in a mammal. When used as a live vaccine, the 2C chimeric virus can be administered alone or in a suitable diluent such as saline or water. The vaccine of the invention may be administered to the mammal by a variety of routes including, but not limited to, orally, subcutaneously, intramuscularly or intravenously. A preferred route of administration is orally. Suitable amounts of chimeric hepatitis A virus may range from about approximately 10 3 to about 10 s tissue culture infectious doses (TCID) , more preferably, from about IO 4 to about IO 7 TCID. Those of ordinary skill in the art would readily understand that suitable concentrations of 2C chimeric virus to include in the vaccines of the invention will vary depending on the route of administration chosen. The immunogens of the invention may be administered once or at periodic intervals until a protective titer of anti-HAV antibody is produced. In a preferred embodiment, the vaccine of the invention is administered to mammals selected from the group consisting of humans, apes and monkeys. In an alternative embodiment, the immunogen of the present invention may be a nucleic acid sequence which encodes a 2C chimeric HAV. Where the sequence is a cDNA sequence, the cDNAs and their RNA transcripts may be used to transfect a mammal by direct injection into the liver tissue of the mammal (Emerson, S.U. et al. (1992) J. Virol. , 66:6649-6654, incorporated herein by reference). Alternatively, direct gene transfer may be accomplished via administration of a eukaryotic expression vector containing a nucleic acid sequence of the invention. Suitable routes of administration for a nucleic acid immunogen include, but are not limited to, intramuscular, subcutaneous or intradermal administration. Eukaryotic expression vectors suitable for producing high efficiency gene transfer __, vivo are known to those of ordinary skill in the art and include, but are not limited to, plasmid-based expression vectors and retroviral and adenoviral vectors. _ Doses of nucleic acid sequence effective to elicit a protective antibody response against hepatitis A range from about 250 μg to about 5 mg, more preferably from about 1 mg to 2 mg. The 2C chimeric viruses and the nucleic acid sequences encoding these viruses may be supplied in the form of a kit, alone, or in the form of a pharmaceutical composition. The administration to mammals of either the 2C chimeric genomes or the 2C chimeric viruses of the invention may be for either a prophylactic or therapeutic purpose. When provided prophylactically, the viruses or nucleic acid sequences are provided in advance of any exposure to HAV or in advance of any symptom due to HAV infection. The prophylactic administration therefore serves to prevent or attenuate any subsequent infection of the mammal with HAV. When provided therapeutically, the viruses or nucleic acid sequences are provided at, or shortly after, the onset of infection or disease caused by HAV. The therapeutic administration of the viruses or nucleic acid sequences of the invention thus attenuates the infection or disease. In addition to use as a vaccine, the 2C chimeric genomes and 2C chimeric viruses of the invention can be used to prepare antibodies to HAV. These antibodies can be used directly as antiviral agents or they may be used in immunoassays such as ELISA, Western blotting and immunohistochemistry to detect HAV or HAV proteins. The antibodies of the present invention may be contained in antiserum obtained from a mammal immunized with the 2C chimeric genomes or the 2C chimeric viruses of the invention. Alternatively the antibodies may be polyclonal antibodies purified or partially purified from the antiserum or monoclonal antibodies. The antibodies of the invention may be utilized for pre- or post-exposure passive immunity prophylaxis. All articles or patents mentioned herein are hereby incorporated by reference. The following examples illustrate various aspects of the invention but are in no way intended to limit the scope thereof. Examples Materials and Methods Qslλa. A subclone of the FRhK-4 cell line, 11-1, was used in these studies because growth of HAV in this cloned cell line is more efficient than in the parent cell line (S. U. Emerson, unpublished data) . Cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum, glutamine, non-essential amino acids, 50 μg/ml gentamycin sulfate and 2.5 μg/ml amphotericin B (Fungizone) (10% DMEM) . Reverse transcription. polvmeraBβ chain reaction and DNA sequencing An AGM-27 virus stock consisting of 10% (w/v) liver homogenate in phosphate-buffered saline (pH 7.2) (Tsarev, A. A., et al. (1991) J. Gen. Virol.. 72:1677- 1683) was the source of viral RNA for cloning of cDNA fragments generated by reverse transcription-polymerase chain reaction (RT-PCR) . Briefly, RNA was isolated from 5-10 μl of liver homogenate by either the guanidinium isothiocyanate extraction procedure (Chomczymski, P. et al. (1987) Anal. Biochem.. 162: 156-159) or with Trizol reagent (Gibco-BRL, Bethesda, MD) following the manufacturer's instructions. Glycogen (20 μg; Boehringer Mannheim, Indianapolis, IN) was added as a carrier prior to precipitation with isopropanol. The RNA was resuspended in 10 μl sterile water to which 1 μl of a 10 μM stock of reverse primer was added. The solution was heated at 65°C for 3 minutes and cooled at room temperature for 5 minutes to facilitate primer binding to the template. The reverse transcription reaction was performed in a final volume of 20 μl in a reaction mixture consisting of 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.S mM MgCl 2 , 40 U RNasin (Promega Biotech, Madison, WI), 1 mM of each deoxynucleoside triphosphate (dNTP) and 8 U avian myeloblastosis virus reverse transcriptase. After synthesis of cDNA at 42°C for 60 minutes, PCR amplification was performed in a total volume of 100 μl of 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl 2 , 0.2 mM of each dNTP, 4 U Taq polymerase (Perkin-Elmer Corp, Norwalk, CT) and 0.5 mM each of forward and reverse primers. When necessary, silent mutations were incorporated into the primers to generate restriction enzyme sites required for subsequent cloning steps. PCR reaction consisted of 35 cycles of 1 minute of incubation at 94 β C, 1 minute of incubation at 45°C and 1-3 minutes of incubation at 72°C followed by a single cycle at 72 β C for 10 minutes. A second round of PCR using nested primers was performed if necessary. The PCR products were purified from low melting agarose gels by phenol extraction or with a gel purification kit (Qiagen, Chatsworth, CA) . All PCR generated fragments or clones containing PCR generated DNA were sequenced using either Sequence (United States Biochemical Corp., Cleveland, OH) following the manufacturer's instructions or the Applied Biosystems 373A automated DNA sequencer using a modified Sanger method. cDNA clones All nucleotide number assignments herein are based on the genomic map of wild-type HM-175 shown in Figure 12 (which corresponds to Figure 1 of Cohen et al. (1987) J. Virol.. 61:50-59). The pHAV/7 plasmid (Cohen, J. I., et al. (1987) Proc. Natl. Acad. Sci.. 84:2497-2501, the pHAV/7 plasmid was deposited with the American Type Culture Collection (ATCC) on August 7, 1987 and has ATCC accession number 67495) was modified by oligonucleotide- directed mutagenesis to include a PpuMl site at nucleotide (nt) 3987-3993 (plasmid 32Y; S. U. Emerson and Y. K. Huang, unpublished results) . In addition, HAV/7 has a naturally occurring EcoRI site at nucleotides 4977-4982 near the 3' end of the 2C gene. As this site was not present in the AGM-27 consensus sequence, an EcoRI site was engineered at the analogous position in the AGM-27 gene (T- * C mutation at AGM nt 4982) by primer-directed mutagenesis using PCR. To facilitate cloning of intragenic chimeras in 2C, 32Y was further mutagenized using PCR (A-»G mutation at nt 4358) to include an Aflll site at nt 4353-4358 (plasmid pGRl) . A natural Aflll site is present at this position in the AGM-27 consensus sequence. The pGR2 chimera was generated by cloning the PpuMl-EcoRI fragment of the AGM-27 consensus sequence (AGM-27 genomic sequence is disclosed in SEQ. ID. NO:l in U.S. Patent No. 5,476,658; the AGM-27 virus was deposited with the ATCC on August 24, 1992 and has ATCC accession number VR 2380) (nt 3996-4981 of AGM-27 2C gene, which encodes amino acids 1-328 of the 2C gene) into the HAV/7 background of p32Y. The 2C gene of pGR2 had three nucleotide differences from the AGM-27 consensus sequence at positions 4211 (C to T transition) , 4280 (G to A transition) and 4397 (T to C transition) but none changed the amino acid sequence. Because the EcoRI site at nt 4977-4982 was used for cloning, the pGR2 plasmid contained a glutamic acid residue which is present in HAV/7 at amino acid position 331 in 2C instead of a lysine residue which is present in the AGM-27 consensus sequence. Thus, of the 31 amino acid differences between the 2C protein of AGM-27 and HAV/7, 30 are present in GR2. The chimera pGR3 was generated by cloning the PpuMl-Aflll fragment from plasmid pGR2 (AGM-27 2C nt sequence 3996 - 4357, which encodes amino acids 1-121 of the 2C gene) into pGRl. The chimera pGR4 was generated by cloning the Aflll-EcoRI fragment from plasmid pGR2 (AβM-27 2C nt sequence 4354 - 4981, which encodes amino acids 120- 328 of the 2C gene) into pGRl. 17 and 13 of the 31 amino acid differences between the 2C proteins of AGM-27 and HAV/7 are present in GR3 and GR4, respectively. Similarly, the PpuMl-Aflll or Aflll-EcoRI segments of pGR2 were replaced with wild-type HM-17S sequences to generate clones pGR14 and pGR13, respectively (Figure 1) . The pGR15 clone contained AGM-27 sequence of 2B from nt 3758-3988. The pGR9 plasmid contained the truncated AGM-27 2B sequence and 2C sequences from nt 3758-4981 in the HAV/7 background (Figure 1) . Establishment of Virus Stock. All full-length cDNAs were cloned in pGEMl (Promega Biotech) . In vitro transcription and transfection assays were performed as described previously by Emerson et al. (Emerson, S. U., et al. (1991) J. Virol.. 65:4882-4886) with a few modifications. Briefly, Sp6 polymerase (Promega Biotech) transcripts synthesiied from 5 μg of DNA linearized with Haell were transfected without purification into ll-l cells. Transfection of cells was accomplished by the DEAE-dextran method. One week after transfection, half of the cells in each flask were passaged to coverslips and the fraction of cells which contained viral antigen was estimated by immunofluorescence microscopy (Emerson, S. U. , et al. (1991) J. Virol.. 65:4882-4886). Transfected cells were harvested by trypsinization when >80% of the cells were infected. Viruses were released from the harvested cells by at least three cycles of freeze-thawing to generate the working virus stocks. RIFA was used to determine focus size of different chimeric viruses and to quantify virus titers. RIFA was a modification of that described by Lemon et al. (1983) (J. Clin. Microbiol.. 17:834-839) and Anderson et al. (1987) ("Positive Strand RNA Viruses" MA Brinton and RR Reichert (ed.) AR Liss Inc. NY) and was essentially performed as previously described (Funkhouser, A. W., et al. (1994) J. Virol., 68:148-157). Cells (11-1) were grown on Thermolux round 25mm coverslips fixed to the bottom of each well in 6-well plates. Virus was adsorbed to cells for 2-4 hours at 34.5°C in a C0 2 incubator. Infected cells were overlaid with 5 ml of 0.5% agarose medium and incubated at 34.5°C in a C0 2 incubator for 10 days. Cells were fixed with acetone and were either processed immediately or stored at -20°C. Viral antigen was detected with a primary antibody consisting of chimpanzee hyperimmune serum (S. U. Emerson, unpublished results) and a secondary antibody of m I-labelled sheep anti-human IgG F(ab * ) 2 fragment (Amersham Corporation, Arlington Heights, IL) . Foci were visualized by autoradiography. Growth Curve Assays Growth curve assays were performed to evaluate the relative rates of replication of viruses in 11-1 cells. Cell monolayers which were >80% confluent in 96- well plates (Falcon) were infected with 0.2 ml of virus diluted in 10% DMEM at a multiplicity of infection of 6 radioimmunofocus-forming units (RFU) per cell. Cells were incubated with virus for 2-4 hours at 34.5°C in a CO j incubator after which the cells were washed 4 times with 10% DMEM and overlaid with 0.2 ml 10% DMEM. At various times, the medium overlaying the cells, which contained 5 virus released from cells, was removed and saved and the volume was adjusted to 0.3 ml with 10% DMEM. The adherent cells in the wells were washed once with 0.2 ml trypsin solution at room temperature and were subsequently incubated with 0.1 ml trypsin solution at 34.5°C until the JO cells exhibited a rounded morphology. The trypsinized cells were then harvested by vigorous pipetting and combined with the medium that had been previously removed. The total virus sample (0.4 ml) was stored at -80°C. Cells were lysed by at least three cycles of freeze- j « j thawing and virus was quantified either by slot blot hybridization or by RIFA. Either HAV/7 or a modified clone of HAV/7 containing a silent mutation was used as a standard in these experiments to measure growth of the fully cell culture-adapted virus. Since there was no 0 significant difference in the growth properties of these two viruses, they were used interchangeably and for simplicity, are always referred to as HAV/7 in this study. Slot Blpt Hybridization RNA was isolated from growth curve samples using 5 Trizol reagent (Gibco-BRL) according to the manufacturer's instructions with the following modifications: A 130 μl aliquot of sample was extracted with an equal volume of Trizol. After the 15 minute centrifugation step to separate the aqueous and organic phases, 100 μl of the 0 aqueous phase was removed and added to 320 μl of a 1:1 solution of 10X SSC (IX SSC is 0.15 M NaCl and 0.015 M sodium citrate (pH 7.0)) and formaldehyde. Viral RNA was quantified by slot blot analysis using a negative strand M P-labelled RNA probe spanning the complete HAV/7 genome. 5 Hybridization was at 50°C for at least 16 hours. Blots were washed three times for 30 minutes each with 2X SSPE (IX SSPE is 10 mM sodium phosphate, 0.18 M NaCl, 1 mM EDTA (pH 7.4)) with 0.1% sodium dodecyl sulphate (SDS) at room temperature and once with 0.1X SSPE, 0.1% SDS at 64°C for one hour. Autoradiography was performed and a Deskscan II scanner (Hewlett Packard) with NIH Image analysis package (Wayne Rasband, public domain software, Bethesda, MD) was used to quantify viral RNA from each time point in the growth curve. At least two or more sister clones were assayed for each virus construct. Virulence Studies in T * T "f T, Bi Tlff The ability of AGM-27 2C chimeras GR2, GR3 and GR4 to cause disease in tamarins was evaluated. Each of two tamarins for each chimera was inoculated intravenously with approximately IO 3 - 8 tissue culture infectious dose equivalents of the GR2 virus in a 0.5 ml volume of inoculum or with approximately IO 48 tissue culture infectious dose equivalents of the GR3 or GR4 viruses in a 0.5 ml volume of inoculum. The estimated number of genome equivalents in the inoculum was determined by RIFA. Blood samples were collected and needle liver biopsies were performed weekly on each animal for at least 2 weeks before and 16 weeks after inoculation with virus. The blood samples were analyzed for seroconversion to anti-HAV with a commercial assay (Abbott Laboratories, North Chicago, IL) and for serum alanine amino transferase (ALT) and isocitrate dehydrogenase (ICD) levels with standard techniques (Metpath, Rockville, MD) . Histopathology was determined under code and scored on a scale of l to 4 depending on the severity of the hepatitis; 1 corresponded to mild hepatitis and 4 to severe hepatitis. Stool samples from the GR2, GR3 or GR4- inoculated tamarins were also analyzed for the presence of excreted virus by RT-PCR. Briefly, a 10% (w/v) suspension of stool in 10 mM Tris (pH 7.0) and 0.135 M NaCl was prepared in a and clarified by low-speed centrifugation to remove large particulate matter. Viral RNA was extracted from a 100 μl aliquot of clarified sample with 1 ml Of Trizol reagent (Gibco-BRL) following the manufacturer's instructions and RT-PCR was performed to amplify a specific region of the viral genome. The amplified DNA was purified with a PCR fragment purification kit (Qiagen) and was sequenced to determine the identity of the excreted virus. Virulen.ee Studies Tn Chimpanzees Two chimpanzees each were inoculated intravenously with approximately 10 s tissue culture infectious dose equivalents of either the GR4 or GR2 virus in a 0.5 ml volume of inoculum. Blood samples were collected and needle liver biopsies were performed we#kly on each animal for at least 2 weeks before and 16 weeks after inoculation with virus. The blood samples were analyzed for seroconversion to anti-HAV with commercial assay and for serum alanine amino transferase (ALT) and isocitrate dehydrogenase (ICD) levels. Histopathology was determined under code and scored on a scale of 1 to 4 as for the tamarins. The housing, maintenance, and care of all animals met or exceeded all requirements for primate husbandry. Example 1 Construction of Chimeras between AGM-27 and HM-17§ The 2B and 2C gene products are the most important determinants of efficient growth of HAV in cell culture (Emerson, S. U. , et al. (1992) J. Virol.. 66:650- 654) . Chimeras containing the AGM-27 truncated 2B and/or 2C gene in the background of the cell culture-adapted HM- 175 virus genome were constructed aβ described in the methods section and are shown schematically in Figure 1. The 2C gene was further subdivided and intragenic chimeras between the simian and human 2C genes were generated (Figure 1, GR3 and GR4) . The amino acid sequence differences between the HM-175 (for either wide-type or HAV/7) and AGM-27 2C proteins are clustered at the amino- terminus and carboxy-terminus of the protein (Figure 2) . The intragenic 2C chimeras were constructed in order to evaluate the effect of separating the two clusters of amino acid residues at the ends of the 2C protein, which differ between HM-175 and AGM-27, from each other. Results obtained with these chimeras are described in the following Examples. Example 2 RIFA of HAV/7. AGM-27 and the GR2 Chimera The radioimmunofocus assay is one method which can be used to evaluate the relative growth properties of viruses. The cell culture-adapted HM-175 virus (HAV/7) grew well in cell culture and formed large foci (Figure 3) . AGM-27, which is a wild-type virus, clearly grew in cell culture but had a small focus phenotype (Figure 3) . By comparison, wild-type HM-175 grew so poorly that visible foci were not detected by this assay (data not shown) . Replacement of the HAV/7 2C gene with AGM-27 sequences (chimera GR2) drastically reduced the ability of the virus to grow (Figure 3) . The only differences between HAV/7, which formed large foci, and the chimera GR2, which had a small focus phenotype, are in the 2C gene, demonstrating the significant contribution of the sequences in 2C to growth of HAV in cell culture. Example 3 RIFA of HAV/7 and Chimeras GR2. GR3. GR4. GR15 and GR9 Replacement of the 2C gene of HAV/7 with AGM-27 sequences drastically reduced the size of the foci that were formed (Figure 4B) . The simian-human intragenic 2C chimeras GR3 and GR4 formed intermediate sized foci (Figures 4C and 4D) . Replacement of the HAV/7 truncated 2B gene with AGM-27 sequences decreased the size of the foci only slightly, if at all (Figure 4E) . However, a chimera containing both the AGM-27 truncated 2B gene and 2C gene in the HAV/7 background formed foci that were even smaller (Figure 4F) than those formed by the chimera containing only the AGM-27 2C gene, again demonstrating the negative influence of the AGM-27 truncated 2B sequence in the context of the homologous 2C. Example 4 Kinetic Studies Showing Relative Growth Rates of HAV/7 and the Chimeras Kinetic studies were conducted as a quantitative measure of the relative growth efficiencies of HAV/7 and the chimeric viruses. Cells were infected with a high multiplicity of virus (6 radioimmunofocus units (RFU)/cell) to ensure that almost every cell was infected. Increase in virus titer over time was therefore a measure of virus replication. RNA was extracted from samples harvested at each time point and quantified by slot blot hybridization and densitometry. Comparison of growth of HAV/7 with a chimera containing the AGM-27 2C gene in this same background (GR2) shows that consistent with the small focus phenotype for GR2 shown previously (Figure 3) the AGM-27 2C sequences greatly reduced the ability of the virus to grow (Figure 5) . Substitution of the cell culture-adapted 2C gene with that from the wild-type human virus also reduced the growth potential of the virus (36Y) although not as drastically as that observed with the simian-human chimera (Figure 5) . The relative rates of growth of HAV/7 and the 2C chimeras as measured by RIFA were similar to that observed by slot blot analysis (data not shown) . Both assays were performed for most chimeras studied and there consistently was good correlation between the results obtained by the two assays. Kinetic assays were also performed to evaluate the ability of the intragenic 2C chimeras to grow in cell culture. Quantitation was again by slot blot hybridization and densitometry. Chimeras containing AGM- 27 sequences in either half of 2C (GR3 and GR4) had an intermediate growth phenotype (Figure 6) as they grew less well than HAV/7 but better than the chimera containing the entire AGM-27 2C sequence (GR2) . These data demonstrate that the clusters of amino acid residues that are unique to AGM-27 at either end of the 2C protein have a negative effect on growth and that this effect is additive. Growth of the GR4 chimera was especially sensitive to the status of the cells and GR4 grew at a rate slightly greater or less than that of the GR3 chimera in different experiments. In every case however, it grew significantly less well than did HAV/7, Kinetic studies were also performed with chimeras containing wild-type HM-175 sequence in one half and AGM-27 sequences in the other half of 2C in the HAV/7 background (GR13 and GR14; Figure 1) . These chimeras grew but not as well as the analogous chimeras containing HAV/7 sequences instead of wild-type HM-175 sequence (data not shown) , again emphasizing the importance of the mutations in 2C that were acquired during passage of HM-175 in cell culture. The truncated AGM-27 2B gene by itself in the HAV/7 background (GR15) had only a minor effect, if any, on virus growth (Figure 7) . However in conjunction with the homologous 2C (GR9) , the truncated AGM-27 2B gene consistently had a significant negative effect on virus growth (Figure 7) . The results of the kinetic studies presented in Figures 5-7 were consistent with the relative sizes of the foci observed for the different chimeric viruses. Moreover, the RIFA and kinetics studies demonstrated that the 2C gene is a major determinant of the efficiency of growth in cell culture and that the AGM- 27 2C gene significantly decreases the ability of HAV/7 to grow in cell culture. In addition, the fact that the. intragenic chimeras GR3 and GR4 are viable and grow at intermediate levels suggests that each cluster of sequence differences present at the ends of the 2C gene in AGM-27 has a negative effect on growth. Example 5 Virulence Studies in Tamarins of the Chimeras GR2. GR3 and GR4 AGM-27 is virulent in tamarins but attenuated in chimpanzees (Emerson, S. U. , et al. (1996) J. Infect. Dis.. 173:592-597) while HAV/7 has an attenuated phenotype in tamarins (Cohen, J. I., et al. (1989) J. Virol.. 63:5364-5370). The GR2, GR3 and GR4 chimeras were each inoculated into two tamarins intravenously and serum liver enzyme levels, antibody titers and liver pathology were evaluated. The pattern of changes in ICD and ALT levels during the course of infection of all animals were similar. The results presented in Figures 8A and 8B show that the GR2 chimera was virulent in tamarins, causing significant increases in serum liver enzyme levels and seroconversion for HAV by week 5 after inoculation. Liver histology showed mild (1+) to moderate (2+) hepatitis 6-9 weeks after inoculation in one animal (Figure 8A) and mild (1+) to moderately severe (3+) hepatitis 5-8 weeks after inoculation in the second animal (Figure 8B) . Virus specific RT-PCR amplification of fecal samples from weeks 5, 6 and 7 were positive either after one round (weeks 5 and 6) or after two rounds (week 7) of PCR with nested primers. A significant amount of virus was therefore being excreted concurrent with the peak elevation of liver enzyme values in the serum and seroconversion in the animals. Partial sequence analysis of virus genomes amplified from the stool samples showed that the sequence of the excreted virus was the same as that of the chimeric virus in the inoculum. These results demonstrate that the 2C gene of AGM-27 can confer the phenotype of virulence for tamarins to an otherwise attenuated virus (HAV/7) . Tamarins inoculated with a chimera containing AGM-27 sequence in the 5' half of the 2C gene in the HAV/7 background (GR3) showed no significant increase in serum liver enzyme levels in either animal (Figures 9A and 9B) . Seroconversion occurred 7 weeks after inoculation in one animal (Figure 9A) but the level of anti-HAV antibodies was relatively low. There was seroconversion in the second animal in week 15. (Figure 9B) . Tamarins inoculated with a chimera containing AGM-27 sequence in the 3' half of the 2C gene in the HAV/7 background (GR4) seroconverted at 6 weeks after inoculation (Figures IOA and 10B) . The serum liver enzyme level was slightly elevated in one animal (Figure IOA) and showed no significant increase in the second animal (Figure 10B) . The data from these tamarin studies suggest that the 2C gene plays a critical role in virulence of HAV in tamarins and that the AGM-27 sequence at the 3' half of the 2C gene appears to make a greater contribution to this phenotype than the AGM-27 sequence at the 5' half of the 2C gene. Example 6 Virulence of the GR2 and GR4 Chimeras in Chimpanzees Chimpanzees inoculated with the GR4 chimera seroconverted either 8 or 15 weeks after inoculation (Figures 11A-11D) and chimpanzees inoculated with the GR2 chimera seroconverted either 7 or 17 weeks after inoculation (Figures 12A and 12B) . None of the animals had any increase in serum liver enzyme levels (Figures 11A-11D, 12A and 12B) . Example 7 Summary of The data from the tamarins and chimpanzees inoculated with the HAV/7/AGM-27 chimeras The data from the tamarin and chimpanzee studies are summarized in Table 1. TABLE 1 Peak Peak Seroconversion ICD ICD Anti-Hav Tamarin Virus (week) (week) value 782 GR2 5 6 5190(1)' 1:16000 783 GR2 5 6 7520(2) * 1:32000 808 GR3 7 none baseline 1:200 790 GR3 15 none baseline 1:1600 799 GR4 6 7 1236(2)' 1:8000 818 GR4 6 none baseline 1:1600 Peak Peak BaWjmjlr Seroconversion ALT ALT Anti-Hav Chimpanzee Virus (week) (week) valμe tilEC 1545 GR2 8 none baseline 1:200 1547 GR2 17 none baseline 1:40 1558 GR4 10 none baseline 1:800 1564 6R4 8 none baseline 1:40 * The number within the brackets refers to the number of weeks that the serum ICD level was above the baseline value. The GR2 and GR4 chimeras thus appear to be attenuated in both tamarins and chimpanzees. These results suggest that the GR2 and GR4 chimeras may function as live attenuated vaccines to offer protection against challenge with human virulent HAV. Example 8 Challenge of Chimpanzees Inoculated With AGM-27/HAV/7 Chimera Chimpanzees are inoculated with IO 5 tissue culture infectious dose equivalents of GR4 virus either by the oral, intramuscular, intradermal or intravenous route of infection. Blood samples are collected and needle liver biopsies are performed weekly on each animal for at least two weeks before inoculation and for the duration of the study. The blood samples are analyzed for seroconversion to anti-HAV by a commercial assay (Abbott Laboratories, North Chicago 111.) and for serum alanine amino transferase (ALT) and isocitrate dehydrogenase (ICD) levels with standard techniques. Liver tissue will also be examined for signs of hepatitis. Three months after antibodies are first detected in serum using a commercial assay, the animals are challenged with 10 3 to 10* chimpanzee dose equivalents of virulent HAV (HM-175 or SD- 11) . After challenge with the virulent strain of HAV, the animals are protected as measured by biochemical (ALT or ICD) , serological (levels of anti-HAV antibodies) and histopathological analyses of the animals for several months after challenge.

Claims: CLAIMS 1. A DNA construct comprising a genome of a hepatitis A virus, said genome being a human attenuated hepatitis A virus genome in which a region of the 2C gene of the attenuated hepatitis A virus genome has been replaced by a corresponding region from a 2C gene of a simian AGM-27 hepatitis A virus genome. An RNA transcript of the DNA construct of claim 1 3. A cell transfected with the DNA construct of claim 1. A cell transfected with the RNA transcript of claim 2. 5. A hepatitis A virus having a genome comprising a human attenuated hepatitis A virus genome in which a region of the 2C gene of the attenuated hepatitis A virus genome has been replaced by a corresponding region of the 2C gene from a simian AGM-27 hepatitis A virus genome. 6. A vaccine for preventing hepatitis A in a mammal, said vaccine comprising the DNA construct of claim 1 and pharmaceutically acceptable carrier. 7. A vaccine for preventing hepatitis A in a mammal, said vaccine comprising the RNA transcript of claim 2 and pharmaceutically acceptable carrier. 8. A vaccine for preventing hepatitis A in a mammal, said vaccine comprising the hepatitis A virus of claim 5 and pharmaceutically acceptable carrier. 9. A method for preventing hepatitis A virus in a mammal, said method comprising administering to said mammal the DNA construct of claim 1 in an amount effective to stimulate the production of protective antibodies in said mammal. 10. A method for preventing hepatitis A virus in a mammal, said method comprising administering to said mammal the RNA transcript of claim 2 in an amount effective to stimulate the production of protective antibodies in said mammal. 11. A method for preventing hepatitis A virus in a mammal, said method comprising administering to said mammal the hepatitis A virus of claim 5 in an amount effective to stimulate the production of protective antibodies in said mammal. 12. A pharmaceutical composition comprising the DNA construct of claim 1. 13. A pharmaceutical composition comprising the RNA transcript of claim 2. 14. A pharmaceutical composition comprising the hepatitis A virus of claim 5. 15. Antibodies to the hepatitis A virus of claim 5. 16. A pharmaceutical composition comprising the antibodies of claim 15. 17. A kit for the prevention of hepatitis A in a mammal, said kit comprising the DNA construct of claim 1 18. A kit for the prevention of hepatitis A in a mammal, said kit comprising the RNA transcript of claim 2 (FEASIBLE?) . 19. A kit for the prevention of hepatitis A in a mammal, said kit comprising hepatitis A virus of claim 5 (FEASIBLE?) . 20. A host cell containing the hepatitis A virus of claim 5. 21. The DNA construct of claim l, wherein the region of the 2C gene from a simian AGM-27 virus genome contained in said construct encodes amino acids 120-328 of the 2C gene. 22. The DNA construct of claim 1, wherein the region of the 2C gene from a simian AGM-27 virus genome contained in said construct encodes amino acids 1-121 of the 2C gene. 23. The DNA construct of claim 1, wherein the region of the 2C gene from a simian AGM-27 virus genome contained in said construct encodes amino acids 1-328 of the 2C gene. 24. Use of a DNA construct according to claim 1 for the manufacture of a medicament for use in a method of preventing hepatitis A in a mammal, comprising administering the medicament to the n-ammal in an amount effective to stimulate the production of protective antibodies. 25. Use of a RNA transcript according to claim 2 for the manufacture of a medicament for use in a method of preventing hepatitis A in a mammal, comprising administering the medicament to the niammal in an amount effective to stimulate the production of protective antibodies. 26. Uβe of a hepatitis A virus according to claim 5 for the manufacture of a medicament for use in a method of preventing hepatitis A in a mammal, comprising administering the medicament to tha mammal in an amount effective to stimulate the production of protective antibodies.

Inventors: EMERSON SUZANNE U, PURCELL ROBERT H, RAYCHAUDHURI GOPA, EMERSON, SUZANNE, U., PURCELL, ROBERT, H., RAYCHAUDHURI, GOPA
Applicants: EMERSON SUZANNE U, PURCELL ROBERT H, RAYCHAUDHURI GOPA, US HEALTH, EMERSON, SUZANNE, U., PURCELL, ROBERT, H., RAYCHAUDHURI, GOPA, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, RE
Application year: 1997
Main classification: C12N15
IPC codes: A61K31, A61K39, A61P31, C07K14, C07K16, C12N5, C12N7, C12N15, C12R1